Patti Francesco, Visconti Andrea, Capacchione Antonio, Roy Sanjeev, Trojano Maria
Azienda Ospedaliera-Universitaria, "Policlinico Vittorio Emanuele", Catania via Santa Sofia 78, Catania, 95123, Italy.
Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.
Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685. doi: 10.1177/1756286420922685. eCollection 2020.
The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry.
Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan-Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model.
Time span under observation in the Italian MS Registry was 1-137 (median 80.3) months. In the total Italian patient population ( = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5-39.5) months.
CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.
CLARINET-MS研究通过利用意大利多发性硬化症(MS)登记处的数据,对意大利的MS患者进行随访,评估了克拉屈滨片的长期疗效。
从意大利MS登记处获取了来自17个MS中心参与克拉屈滨片随机临床试验(RCT;CLARITY、CLARITY扩展、ONWARD或ORACLE-MS)的意大利MS患者的真实世界数据(RWD)。RWD是在设定的观察期内收集的,从RCT期间克拉屈滨片的最后一剂(定义为基线)到登记处的最后就诊日期、转用其他疾病修饰药物、最后一次扩展残疾状态量表记录日期或最后一次复发日期(以最后发生者为准)。使用Kaplan-Meier(KM)方法完成事件发生时间分析。从模型中估计中位持续时间和相关的95%置信区间(CI)。
意大利MS登记处的观察时间跨度为1至137个月(中位值80.3个月)。在意大利患者总数(n = 80)中,最后一剂克拉屈滨片后12、36和60个月无复发概率的KM估计值分别为84.8%、66.2%和57.2%。最后一剂后第60个月无疾病进展的相应概率为63.7%。最后一剂克拉屈滨片后60个月未开始另一种疾病修饰治疗概率的KM估计值为28.1%,治疗改变的中位时间为32.1(95%CI 15.5 - 39.5)个月。
CLARINET-MS提供了克拉屈滨片长期疗效的间接测量。超过一半的分析MS患者在最后一剂后的60个月随访期间未复发或出现残疾进展,这表明克拉屈滨片在第1年和第2年初短期用药后的第3年和第4年仍然有效。